Jubilant Life Sciences has soared 18% to Rs 105 on back of heavy volumes on the BSE. A combined 3.85 million shares representing nearly 5% of free-float equity of the company have changed hands so far against an average sub one million shares that were traded daily in past two weeks on BSE and NSE.
The stock has rallied nearly 45% in past three trading sessions from Rs 72.50 on Monday on reports that the company may delist its equity shares from Indian bourses.
“Jubilant Life Sciences aimed to raise $150-200 million through the initial public offering, might soon list itself on the New York Stock Exchange (NYSE),” the Business Standard report suggests.
The company equity shares currently listed on the BSE and NSE may delist its shares from Indian bourses, added report.
Meanwhile, a global pharmaceutical and life sciences firm that manufactures and supplies active pharmaceutical ingredients, generics and life science ingredients said it has received ANDA approvals for Bupropion Hydrochloride from US FDA and expect to launch the same in December quarter.
The current total market size of these products as per IMS is $518 million per annum. The company expects to launch these products in Q3 FY14, Jubilant Life Sciences said in a statement.
The stock has rallied nearly 45% in past three trading sessions from Rs 72.50 on Monday on reports that the company may delist its equity shares from Indian bourses.
“Jubilant Life Sciences aimed to raise $150-200 million through the initial public offering, might soon list itself on the New York Stock Exchange (NYSE),” the Business Standard report suggests.
The company equity shares currently listed on the BSE and NSE may delist its shares from Indian bourses, added report.
Meanwhile, a global pharmaceutical and life sciences firm that manufactures and supplies active pharmaceutical ingredients, generics and life science ingredients said it has received ANDA approvals for Bupropion Hydrochloride from US FDA and expect to launch the same in December quarter.
The current total market size of these products as per IMS is $518 million per annum. The company expects to launch these products in Q3 FY14, Jubilant Life Sciences said in a statement.